OR WAIT null SECS
September 24, 2015.
Despite few products having so far reached the market, the gene therapy pipeline remains large, states a GBI Research report.
There are currently 906 products in active development across all stages, although the majority are early-stage, says the report. Oncology is the most active pipeline sector, with gene therapies in development, more than double that of central nervous system disorders, which is the second-largest therapy area. Oncology also accounted for 64% of gene therapy clinical trials between 1989 and 2012. The other main gene therapy sectors in active development are infectious diseases, genetic disorders, cardiovascular diseases and ophthalmological indications.
The report also states that, based on pipeline activity, Isis Pharmaceuticals is a major player in the gene therapy R&D space, with 31 gene silencing-based programs in development across the key therapy areas. Sarepta and Alnylam Pharmaceuticals are also key players, with 25 and 24 pipeline products in development, respectively.
See the report, Gene Therapy: A Diverse Range of Technologies with a Promising Long-Term Outlook, here.